Qihan Bio Reports Positive Preliminary Clinical Data for Its In Vivo CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
This morning,Qihan Biotech Reports Preliminary Positive Clinical Data for Its In Vivo CAR-T Therapy
This is the third in vivo CAR-T therapy to disclose clinical data in the recent period.
Hangzhou Qihan Biotech Co., Ltd. has not disclosed specific information on its in vivo CAR-T pipeline.
Only KnownHangzhou Qihan Biotech Co., Ltd.'s first in vivo CAR-T project is aDual-targeted in vivo CAR-T therapy, developed for the treatment of multiple myeloma, is based on QiQihan BiotechExclusiveDeveloped based on the precision-targeted in vivo CAR-T platform technology,Possesses non-specific effects that evade tumor cells and phagocytes, precisely targets T cells, and resolves the issue of antigen masking, thereby ensuring the safety and long-term efficacy of in vivo CAR-T therapy.
According toThe report released by Qihan Biotech at the ASH 2025 Annual Meeting shows that,Qihan Biotech has developed a lentivirus-based in vivo CAR-T platform, through theBinder-Designed envelope protein reduces cytokine release, precisely controls early T-cell stimulation, and exhibits rapid receptor internalization without sustained formation of TCR signaling complexes, thereby maintaining the metabolic profile of resting T cells and preventingExhaustionUpregulation of markers, thereby maintainingAchieving high specificity and built-in safety features in the functionally quiescent state of T cells“Silent” CAR Delivery.
Currently,Hangzhou Qihan Biotech Co., Ltd.'sThe in vivo CAR-T project has advanced to the clinical stage, with an investigator-initiated trial (IIT) currently underway; four cases have been enrolled.Administration to patients with refractory multiple myeloma.
The latest disclosed data show:No serious safety events were observed, meeting the safety criteria for outpatient administration. The first two patients who completed the 1-month follow-up both achieved complete remission, including a patient with extramedullary involvement (EMI) and an elderly patient who had failed prior autologous CAR-T therapy. The study is ongoing.
In fact, since late 2024, in vivo CAR-T has begun to attract attention from global pharmaceutical giants.
According to statistics,Six Major Corporate Acquisitions in the In Vivo CAR-T SectorEli Lilly, BMS, AbbVie, AstraZeneca, Gilead and other global pharmaceutical giants have all entered the fray, with Eli Lilly alone having acquired two in vivoCAR-T company, encompassing two major in vivo CAR-T technology pathways.
2026On May 31, Kelonia Therapeutics at ASCO2026released the latest data from the Phase 1 clinical study (inMMyCAR) of its in vivo BCMA CAR-T candidate drug KLN-101, which showed:All evaluable patients achieved a 100% objective response rate (ORR) and minimal residual disease (MRD) negativity one month after treatment. June 2, 2026, Legend Biotechreleased preliminary Phase 1 clinical data for its in vivo CAR-T drug LB2501, with the data showing: atIn the dose level 2 (DL2) cohort, the objective response rate (ORR) was 100% (6/6), and the complete response rate (CR) was 83.3% (5/6). As of the data cutoff date, all responses were ongoing. June 5, 2026Qihan Biotech Reported Preliminary Positive Clinical Data for Its In Vivo CAR-T Therapy,Both the first and second patients who completed the 1-month follow-up achieved complete remission.
Another 100% ORR, This Time for Legend’s In Vivo CAR-T
With the release of these positive clinical data, in vivo CAR-T therapies are expected to remain highly promising. Meanwhile, with successive acquisitions by leading pharmaceutical companies, high-quality overseas in vivo CAR-T assets...Target PresentationAmid the trend of increasing scarcity, domestic in vivo CAR-T projects are poised to become the next hotspot for business development (BD).
